Tonix Pharmaceuticals to Participate in Two Investor Conferences in March

Core Insights - Tonix Pharmaceuticals Holding Corp. is participating in two investor conferences in March 2026, highlighting its engagement with the investment community [1][2]. Group 1: Upcoming Conferences - The company will present at the TD Cowen 46th Annual Healthcare Conference on March 4, 2026, with CEO Seth Lederman as the presenter [1]. - Management will be available for one-on-one meetings at the Barclays 28th Annual Healthcare Conference from March 10 to 12, 2026 [2]. Group 2: Company Overview - Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on treatments for central nervous system (CNS) and immunology conditions [3]. - The company's flagship product, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in over 15 years [3]. - Tonix is advancing its CNS portfolio, including products for acute migraines and ongoing Phase 2 clinical trials for major depressive disorder and acute stress disorder [3]. - The company is also developing immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500 for kidney transplant rejection prevention [3].